Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Ultragenyx Pharmaceutical Inc’s stock clocked out at $22.51, down -3.02% from its previous closing price of $23.21. In other words, the price has decreased by -$3.02 from its previous closing price. On the day, 2.75 million shares were traded. RARE stock price reached its highest trading level at $23.9 during the session, while it also had its lowest trading level at $22.5.
Upgrades & Downgrades
In the most recent recommendation for this company, Wells Fargo on October 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $65.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 02 ’26 when Horn Howard sold 3,150 shares for $22.84 per share. The transaction valued at 71,946 led to the insider holds 91,996 shares of the business.
HOWARD HORN bought 3,150 shares of RARE for $71,946 on Jan 02 ’26. On Dec 29 ’25, another insider, Huizenga Theodore Alan, who serves as the SVP, Chief Accounting Officer of the company, sold 85 shares for $34.38 each. As a result, the insider received 2,922 and left with 50,450 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 2171709952 and an Enterprise Value of 2612680192. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.55 while its Price-to-Book (P/B) ratio in mrq is 236.60. Its current Enterprise Value per Revenue stands at 4.143 whereas that against EBITDA is -5.136.
Stock Price History:
The Beta on a monthly basis for RARE is 0.16, which has changed by -0.47845227 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $46.50, while it has fallen to a 52-week low of $18.41. The 50-Day Moving Average of the stock is -29.44%, while the 200-Day Moving Average is calculated to be -31.26%.
Shares Statistics:
It appears that RARE traded 2.10M shares on average per day over the past three months and 5829850 shares per day over the past ten days. A total of 96.27M shares are outstanding, with a floating share count of 89.78M. Insiders hold about 6.95% of the company’s shares, while institutions hold 98.94% stake in the company. Shares short for RARE as of 1765756800 were 8600577 with a Short Ratio of 4.10, compared to 1763078400 on 7828953. Therefore, it implies a Short% of Shares Outstanding of 8600577 and a Short% of Float of 9.229999999999999.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 12.0 analysts currently analyzing and rating the stock of Ultragenyx Pharmaceutical Inc (RARE).The consensus estimate for the next quarter is -$1.42, with high estimates of -$0.91 and low estimates of -$1.77.
Analysts are recommending an EPS of between -$5.26 and -$6.41 for the fiscal current year, implying an average EPS of -$5.73. EPS for the following year is -$4.16, with 12.0 analysts recommending between -$1.52 and -$6.45.
Revenue Estimates
In. The current quarter, 16 analysts expect revenue to total $189.46M. It ranges from a high estimate of $220.26M to a low estimate of $175.1M. As of. The current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $164.88MFor the next quarter, 16 analysts are estimating revenue of $171.41M. There is a high estimate of $197.47M for the next quarter, whereas the lowest estimate is $145M.
A total of 19 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $685.98M, while the lowest revenue estimate was $641.7M, resulting in an average revenue estimate of $655.9M. In the same quarter a year ago, actual revenue was $560.23MBased on 19 analysts’ estimates, the company’s revenue will be $786.09M in the next fiscal year. The high estimate is $886.7M and the low estimate is $668.72M.
